Proceedings of the conference BioSangam 2022: Emerging trends in Biotechnology (BIOSANGAM 2022)

<Previous Article In Volume
Next Article In Volume>

Nanotechnology in COVID-19 Vaccines

Authors
Ananya Jain1, Shilpa Sharma1, 2, *
1Department of Biological Sciences and Engineering, Netaji Subhas Institute of Technology, Azad Hind Fauj Marg, Sector-3 Dwarka, New Delhi, 110078, India
2Department of Biological Sciences and Engineering, Netaji Subhas University of Technology, Azad Hind Fauj Marg, Sector-3 Dwarka, New Delhi, 110078, India
*Corresponding author. Email: Shilpa.sharma@nsut.ac.in
Corresponding Author
Shilpa Sharma
Available Online 14 December 2022.
DOI
10.2991/978-94-6463-020-6_3How to use a DOI?
Keywords
SARS-COV-2; Vaccines; Infectious Diseases; Nanotechnology; mRNA vaccine
Abstract

Nanotechnology has been proposed in vaccine development as carriers and adjuvants time and again but received limited recognition before the development of vaccines for the COVID-19 pandemic. Nanotechnology has played a pivotal role in the triumph of the vaccines for the current pandemic caused by the SARS-CoV-2 virus. The first vaccine got approved within a year of the earliest reported case of the novel coronavirus. Presently, more than 35 vaccines are approved in at least one country, 10 out of which are sanctioned for emergency use by the WHO. The key categories include peptide vaccine, mRNA vaccine, inactivated & viral vector vaccines. Nanotechnology is a crucial component in the success of mRNA vaccines. Nanoparticles not only allow targeted drug delivery but also boost the pharmacokinetic profile and the immune response against the therapeutic. A few nanoparticles have received approval for use as adjuvants (MF59), and countless others (virosomes, PGLA) are under development for many vaccines for infectious diseases, for instance, Influenza, Hepatitis B, Human Papillomavirus, Malaria, Tuberculosis, etc. In this article, we will review the vaccines available against SARS-CoV-2 with a focus on the nanotechnology utilized in their development.

Copyright
© 2023 The Author(s)
Open Access
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

<Previous Article In Volume
Next Article In Volume>
Volume Title
Proceedings of the conference BioSangam 2022: Emerging trends in Biotechnology (BIOSANGAM 2022)
Series
Advances in Biological Sciences Research
Publication Date
14 December 2022
ISBN
978-94-6463-020-6
ISSN
2468-5747
DOI
10.2991/978-94-6463-020-6_3How to use a DOI?
Copyright
© 2023 The Author(s)
Open Access
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Cite this article

risenwbib
TY  - CONF
AU  - Ananya Jain
AU  - Shilpa Sharma
PY  - 2022
DA  - 2022/12/14
TI  - Nanotechnology in COVID-19 Vaccines
BT  - Proceedings of the conference BioSangam 2022: Emerging trends in Biotechnology (BIOSANGAM 2022)
PB  - Atlantis Press
SP  - 14
EP  - 26
SN  - 2468-5747
UR  - https://doi.org/10.2991/978-94-6463-020-6_3
DO  - 10.2991/978-94-6463-020-6_3
ID  - Jain2022
ER  -